(Q42704885)

English

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

scientific article published on 6 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert A Hauser

1

object named as

Robert A Hauser

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Charles Warren Olanow

2

object named as

C Warren Olanow

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

6

object named as

Mark Lew

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

author name string

Karl D Kieburtz

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Emmanuelle Pourcher

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Any Docu-Axelerad

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Olexandr Kozyolkin

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Ann Neale

8

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Chris Resburg

9

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Uwe Meya

10

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Christopher Kenney

11

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Stephen Bandak

12

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

6 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

767-776

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

An inventory for measuring clinical anxiety: psychometric properties

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of minimal clinically important change in early and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970148-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70148-6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42704885&oldid=1971260478"